X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TH1902 (Docetaxel-TH19P01 Conjugate) is Theratechnologies’ proprietary peptide drug conjugate (“PDC”) linked, a well-established and well-characterized cytotoxic agent.
Lead Product(s): Docetaxel-TH19P01 Conjugate
Therapeutic Area: Oncology Product Name: TH1902
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Theratechnologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
sNDA is supported by Phase 3 Study 1601 for FINTEPLA® (fenfluramine) for treatment of seizures associated with Lennox-Gastaut Syndrome to FDA. FINTEPLA is approved by the FDA and European Commission for treatment of seizures associated with Dravet syndrome.
Lead Product(s): Fenfluramine
Therapeutic Area: Neurology Product Name: Fintepla
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Zogenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
PPD will manage the Phase 1b/2a clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, also known as FW-420.
Lead Product(s): Niclosamide
Therapeutic Area: Gastroenterology Product Name: FW-420
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2021
Details:
PPD will work with U.S. Army Medical Materiel Development Activity’s Warfighter Brain Health Project Management Office to test the efficacy and safety of at least two pharmacotherapeutic drugs for the treatment of PTSD in U.S. military active duty personnel and veterans.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: US Army
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 18, 2021
Details:
Under the terms of the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022.
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FW-1022
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
